LONDON BROKER RATINGS: RBC prefers Astra to GSK; HSBC cuts Burberry
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
| Price | 11,822.00p on 09-09-2026 at 09:57:27 |
|---|---|
| Change | -54.00p -0.45% |
| Buy | 11,822.00p |
| Sell | 11,818.00p |
| Last Trade: | Buy 79.00 at 11,822.00p |
| Day's Volume: | 390,111 |
| Last Close: | 11,876.00p |
| Open: | 11,850.00p |
| ISIN: | GB0009895292 |
| Day's Range | 11,796.00p - 11,996.00p |
| 52wk Range: | 10,784.00p - 15,730.00p |
| Market Capitalisation: | £183.35b |
| VWAP: | 11,868.43687p |
| Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 79 | 11,822.00p | Automatic Execution |
10:57:15 - 09-Sep-26 |
| Buy* | 31 | 11,822.00p | Automatic Execution |
10:57:15 - 09-Sep-26 |
| Buy* | 10 | 11,818.00p | Automatic Execution |
10:56:57 - 09-Sep-26 |
| Buy* | 11 | 11,816.00p | Automatic Execution |
10:56:56 - 09-Sep-26 |
| Buy* | 3 | 11,816.396p | Ordinary |
10:56:51 - 09-Sep-26 |
| Buy* | 7,572 | 11,819.82p | Ordinary |
10:56:47 - 09-Sep-26 |
| Sell* | 106 | 11,816.00p | Automatic Execution |
10:56:43 - 09-Sep-26 |
| Buy* | 9 | 11,816.00p | Automatic Execution |
10:56:43 - 09-Sep-26 |
| Sell* | 8 | 11,812.00p | SI Trade |
10:56:30 - 09-Sep-26 |
| Buy* | 49 | 11,814.00p | Automatic Execution |
10:56:26 - 09-Sep-26 |
Astrazeneca (AZN) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 8th Sep 2026 2:00 pm | RNS | Imfinzi+Imdelltra improved OS in small cell lung |
| 7th Sep 2026 7:00 am | RNS | Etcamah approved in the US for HR+ breast cancer |
| 1st Sep 2026 3:05 pm | RNS | Admission of Further Securities to Trading |
| 1st Sep 2026 3:00 pm | RNS | Total Voting Rights |
| 1st Sep 2026 11:00 am | RNS | Admission to Trading - €2.55 billion bond offering |
| 1st Sep 2026 7:30 am | RNS | Enhertu approved in EU for 1L HER2-positive mBC |
| 1st Sep 2026 7:10 am | RNS | Directorate change |
| 1st Sep 2026 7:05 am | RNS | AstraZeneca completes agreement for Zegfrovy |
| 1st Sep 2026 7:00 am | RNS | Tagrisso + Orpathys improved PFS in 1L EGFRm lung |
| 27th Aug 2026 7:00 am | RNS | Tezspire CROSSING trial met primary endpoints |